1
|
Di Carlo D, Annereau M, Yoldjian I, Vassal G, Grill J. An academia-driven compassionate use program for patients with recurrent H3K27-altered diffuse midline glioma: a new way to access innovation when clinical trials are lacking. Ann Oncol 2023; 34:826-827. [PMID: 37423297 DOI: 10.1016/j.annonc.2023.06.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Revised: 06/29/2023] [Accepted: 06/29/2023] [Indexed: 07/11/2023] Open
Affiliation(s)
- D Di Carlo
- Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France; Hematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padova, Italy
| | - M Annereau
- Department of Clinical Pharmacy, Gustave Roussy Cancer Campus, Villejuif
| | - I Yoldjian
- National Agency for the Safety of Medicines and Health Products (ANSM), Paris
| | - G Vassal
- Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France
| | - J Grill
- Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France; INSERM U981, "Genomics and Oncogenesis of Pediatric Brain Tumors", Villejuif, France.
| |
Collapse
|
2
|
Minard-Colin V, Aupérin A, Burke A, Alexander S, Moreno M, Buffardi S, Uyttebroeck A, Bollard C, Zsiros J, Csoka M, Kazanowska B, Chiang A, Verschuur A, Miles R, Wotherspoon A, Barkauskas D, Wheatley K, Vassal G, Adamson P, Gross T, Patte C, Pillon M. INTER-B NHL-RITUX-2010 TRIAL FOR CHILDREN/ADOLESCENTS WITH HIGH-RISK MATURE B-NHL: SAFETY AND EFFICACY IN PATIENTS TREATED WITH RITUXIMAB AND LMB CHEMOTHERAPY. Leuk Res 2022. [DOI: 10.1016/s0145-2126(22)00255-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
3
|
Italiano A, Drilon A, Shen L, Hong D, van Tilburg C, Tan D, Lin J, Kummar S, Doz F, Geoerger B, Brose M, Briggs A, Lassen U, Vassal G, Keating K, Norenberg R, Dima L, Brega N, Laetsch T, Garcia-Foncillas J. 464P Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
4
|
Vassal G, Kozhaeva O, Griskjane S, Arnold F, Nysom K, Basset L, Kameric L, Kienesberger A, Kamal S, Cherny N, Bricalli G, Latino N, Kearns P. Access to essential anticancer medicines for children and adolescents in Europe. Ann Oncol 2021; 32:560-568. [PMID: 33388384 DOI: 10.1016/j.annonc.2020.12.015] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Revised: 12/16/2020] [Accepted: 12/20/2020] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND Essential anticancer medicines are an indispensable component of multidisciplinary treatment of paediatric malignancies. A European Society for Medical Oncology (ESMO) study reported inequalities in the availability of anticancer medicines for adult solid tumours and provided a model for the present survey. The aim of this survey was to assess the accessibility of essential medicines used in paediatric cancer patients aged 0 to 18 years across Europe from 2016 to 2018. METHODS A list of medicines was drawn with input from the European Society for Paediatric Oncology (SIOP Europe) Clinical Research Council referring to the World Health Organization Model List of Essential Medicines for Children (WHO EMLc) 2017. A survey was sent to nominated national clinician and pharmacist rapporteurs and parent associations in up to 37 countries; answers were obtained from 34 countries. RESULTS The full survey list contained 68 medicines, including 24 on the WHO EMLc 2017. Health professionals reported that 35% of all medicines were prescribed off-label in at least one country and that 44% were always available in >90% of countries. Only 63% of the EMLc 2017 medicines were reported as always available. The main determinant of unavailability was shortages, reported for 72% of medicines in at least one country. Out-of-pocket costs were reported in eight countries. Twenty-seven percent of orally administered medicines were never available in child-friendly formulations. Parents detailed individual efforts and challenges of facilitating ingestion of oral medicines as prescribed. Inequalities in access to pain control during procedures were reported by parents across Europe. CONCLUSIONS Children and adolescents with cancer in Europe experience lack of access to essential medicines. Urgent actions are needed to address shortages, financial accessibility, availability of safe age-appropriate oral formulations, and pain management across Europe.
Collapse
Affiliation(s)
- G Vassal
- Paediatric Oncology Department, Gustave Roussy, Villejuif, France; Paris-Sud University, Orsay, France; European Society for Paediatric Oncology (SIOP Europe), Brussels, Belgium.
| | - O Kozhaeva
- Policy Department, SIOP Europe, Brussels, Belgium
| | - S Griskjane
- Children's Clinical University Hospital, Riga, Latvia; European Society of Oncology Pharmacy (ESOP), Luxembourg
| | - F Arnold
- Childhood Cancer International - Europe (CCI-E), Montpellier, France
| | - K Nysom
- Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark; SIOP Europe, Brussels, Belgium
| | - L Basset
- CCI-E, Madrid, Spain; Universitat Politècnica de València, Valencia, Spain
| | - L Kameric
- CCI-E, Sarajevo, Bosnia and Herzegovina
| | | | - S Kamal
- Department of Pharmaceutical Services, Children's Cancer Hospital, Cairo, Egypt; ESOP, Luxembourg
| | - N Cherny
- Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel; European Society for Medical Oncology (ESMO), Lugano, Switzerland
| | - G Bricalli
- European Society for Medical Oncology (ESMO), Lugano, Switzerland
| | - N Latino
- European Society for Medical Oncology (ESMO), Lugano, Switzerland
| | - P Kearns
- Institute of Cancer and Genomic Sciences, NIHR Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK; SIOP Europe, Brussels, Belgium
| |
Collapse
|
5
|
Italiano A, Hong D, Briggs A, Garcia-Foncillas J, Lassen U, Vassal G, Kummar S, van Tilburg C, Keating K, Reeves J, Fellous M, Nogai H, Laetsch T, Drilon A. 542P Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.656] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
6
|
Leyvraz S, Yang JH, Casali P, Castro G, Kim E, Lassen U, Lopez-Rios F, Penault-Llorca F, Pappo A, Rudzinski E, Tabatabai G, Vassal G, Reeves J, Nogai H, Fellous M, Drilon A, Brose M, Trent J. 604TiP ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.718] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
7
|
Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, Guibert SD, Barlési F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann Oncol 2019; 30:1985-1991. [PMID: 31584608 DOI: 10.1093/annonc/mdz407] [Citation(s) in RCA: 111] [Impact Index Per Article: 22.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND In 2013, the French National Cancer Institute initiated the AcSé program to provide patients with secure access to targeted therapies outside of their marketed approvals. Efficacy and safety was then assessed using a two-stage Simon phase II trial design. When the study design was designed, crizotinib was approved only as monotherapy for adults with anaplastic lymphoma kinase plus non-small-cell lung cancers (NSCLC). PATIENTS AND METHODS Advanced NSCLC patients with c-MET ≥6 copies, c-MET-mutated, or ROS-1-translocated tumours were enrolled in one of the three cohorts. Patients were treated with crizotinib 250 mg twice daily. Efficacy was assessed using the objective response rate (ORR) after two cycles of crizotinib as primary outcome. Secondary outcomes included disease control rate at four cycles, best ORR, progression-free survival, overall survival, and drug tolerance. RESULTS From August 2013 to March 2018, 5606 patients had their tumour tested for crizotinib targeted molecular alterations: 252 patients had c-MET ≥6 copies, 74 c-MET-mutation, and 78 ROS-1-translocated tumour. Finally, 25 patients in the c-MET ≥6 copies cohort, 28 in the c-MET-mutation cohort, and 37 in the ROS-1-translocation cohort were treated in the phase II trial. The ORR was 16% in the c-MET ≥6 copies cohort, 10.7% in the mutated, and 47.2% in the ROS-1 cohort. The best ORR during treatment was 32% in the c-MET-≥6 copies cohort, 36% in the c-MET-mutated, and 69.4% in the ROS-1-translocation cohort. Safety data were consistent with that previously reported. CONCLUSIONS Crizotinib activity in patients with ROS1-translocated tumours was confirmed. In the c-MET-mutation and c-MET ≥6 copies cohorts, despite insufficient ORR after two cycles of crizotinib, there are signs of late response not sufficient to justify the development of crizotinib in this indication. The continued targeting of c-MET with innovative therapies appears justified. CLINICAL TRIAL NUMBER NCT02034981.
Collapse
Affiliation(s)
- D Moro-Sibilot
- Thoracic Oncology Unit, Grenoble-Alpes University Hospital, Grenoble; Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris.
| | - N Cozic
- Department of Biostatistics and Epidemiology, Gustave Roussy Cancer Campus, INSERM U1018, ESP, Paris-Saclay and Paris-Sud Universities, Villejuif
| | - M Pérol
- Department of Medical Oncology, Léon Bérard Cancer Centre, Lyon
| | - J Mazières
- Pneumology Department, Toulouse University Hospital and Paul Sabatier University, Toulouse
| | - J Otto
- Department of Medicine, Antoine Lacassagne Cancer Centre, Nice
| | - P J Souquet
- Department of Pneumology and Thoracic Oncology, Lyon Sud Hospital Center, Hospices Civils de Lyon, Pierre Bénite
| | - R Bahleda
- Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif
| | - M Wislez
- Pneumology Department, Tenon Hospital, AP-HP and "Pierre and Marie Curie" University, Paris
| | - G Zalcman
- Thoracic Oncology Department-CIC INSERM 1425, Bichat University Hospital, AP-HP, Paris; Paris-Diderot University, Paris
| | | | - F Barlési
- Multidisciplinary Oncology & Therapeutic Innovations Department, APHM and Aix Marseille University, INSERM, CNRS, CRCM, Marseille
| | - B Mennecier
- Pneumology Department, Strasbourg University Hospital, Strasbourg
| | - I Monnet
- Pneumology Department, CHIC Creteil, Créteil
| | - R Sabatier
- Department of Medical Oncology, Inserm 1068, CNRS UMR7258, CRCM, Paoli-Calmettes Institute and Aix-Marseille University, Marseille
| | - S Bota
- Pneumology Department, Charles Nicolle Hospital, Rouen University Hospital, Rouen
| | - C Dubos
- Pneumology Department, François Baclesse Cancer Centre, Caen
| | - V Verriele
- Anatomy and Pathological Cytologies Department, Paul Papin Cancer Centre, ICO, Angers
| | - V Haddad
- Department of Tumour Biology, Léon Bérard Cancer Centre, Lyon
| | - G Ferretti
- Radiology and Medical Imaging Department, Grenoble-Alpes University Hospital, Grenoble
| | - A Cortot
- Department of Thoracic Oncology, Lille University Hospital and University of Lille, Lille
| | - F De Fraipont
- Molecular Genetic Unit: Hereditary Diseases and Oncology, Grenoble-Alpes University Hospital, Grenoble
| | - M Jimenez
- Research and Development UNICANCER, Paris
| | | | - G Vassal
- Clinical Research Division, Gustave Roussy Cancer Campus, Villejuif, France
| |
Collapse
|
8
|
Enrico D, Lacroix L, Rouleau E, Scoazec JY, Loriot Y, Tselikas L, Jovelet C, Planchard D, Gazzah A, Mezquita L, Ngo M, Michiels S, Maillard A, Massard C, Facchinetti F, Soria JC, André F, Vassal G, Friboulet L, Besse B. A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz413.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Mezquita L, Planchard D, Suarez MD, Aldea M, Naltet C, Lamberts V, Grecea M, Martin-Romano P, de Kievit F, Jovelet C, Lacroix L, Masip JR, Lavaud P, Gazzah A, Morris C, Howarth K, Green E, Vassal G, Massard C, Besse B. Clinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz431.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Enrico D, Lacroix L, Rouleau E, Scoazec JY, Loriot Y, Tselikas L, Jovelet C, Planchard D, Gazzah A, Mezquita L, Ngo M, Michiels S, Massard C, Facchinetti F, Chen J, Soria JC, André F, Vassal G, Friboulet L, Besse B. Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: Insights of the MATCH-R study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
11
|
Rodriguez D, Chambers T, Warmuth-Metz M, Aliaga ES, Warren D, Calmon R, Hargrave D, Garcia J, Vassal G, Grill J, Zahlmann G, Morgan PS, Jaspan T. Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas. AJNR Am J Neuroradiol 2019; 40:568-575. [PMID: 30819765 DOI: 10.3174/ajnr.a5982] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Accepted: 12/31/2018] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE HERBY was a Phase II multicenter trial setup to establish the efficacy and safety of adding bevacizumab to radiation therapy and temozolomide in pediatric patients with newly diagnosed non-brain stem high-grade gliomas. This study evaluates the implementation of the radiologic aspects of HERBY. MATERIALS AND METHODS We analyzed multimodal imaging compliance rates and scan quality for participating sites, adjudication rates and reading times for the central review process, the influence of different Response Assessment in Neuro-Oncology criteria in the final response, the incidence of pseudoprogression, and the benefit of incorporating multimodal imaging into the decision process. RESULTS Multimodal imaging compliance rates were the following: diffusion, 82%; perfusion, 60%; and spectroscopy, 48%. Neuroradiologists' responses differed for 50% of scans, requiring adjudication, with a total average reading time per patient of approximately 3 hours. Pseudoprogression occurred in 10/116 (9%) cases, 8 in the radiation therapy/temozolomide arm and 2 in the bevacizumab arm (P < .01). Increased target enhancing lesion diameter was a reason for progression in 8/86 cases (9.3%) but never the only radiologic or clinical reason. Event-free survival was predicted earlier in 5/86 (5.8%) patients by multimodal imaging (diffusion, n = 4; perfusion, n = 1). CONCLUSIONS The addition of multimodal imaging to the response criteria modified the assessment in a small number of cases, determining progression earlier than structural imaging alone. Increased target lesion diameter, accounting for a large proportion of reading time, was never the only reason to designate disease progression.
Collapse
Affiliation(s)
- D Rodriguez
- Medical Physics and Clinical Engineering (D.R., P.S.M.)
| | - T Chambers
- Cardiff University, School of Medicine (T.C.), Cardiff, UK
| | - M Warmuth-Metz
- Würzburg University, Institute for Diagnostic and Interventional Neuroradiology (M.W.-M.), Würzburg, Germany
| | - E Sanchez Aliaga
- VU University Medical Center, Department of Radiology & Nuclear Medicine (E.S.A.), Amsterdam, the Netherlands
| | - D Warren
- Leeds Teaching Hospital, Department of Radiology (D.W.), Leeds, UK
| | - R Calmon
- Assistance Publique-Hôpitaux de Paris, Pediatric Radiology (R.C.), Paris, France
| | - D Hargrave
- Great Ormond Street Hospital, Haematology and Oncology Department (D.H.), London, UK
| | - J Garcia
- F. Hoffmann-La Roche (J.Garcia, G.Z.), Basel, Switzerland
| | - G Vassal
- Gustave Roussy and Paris-Sud University, Pediatric and Adolescent Oncology and Unite Mixte de Recherche (G.V., J.Grill), Villejuif, France
| | - J Grill
- Gustave Roussy and Paris-Sud University, Pediatric and Adolescent Oncology and Unite Mixte de Recherche (G.V., J.Grill), Villejuif, France
| | - G Zahlmann
- F. Hoffmann-La Roche (J.Garcia, G.Z.), Basel, Switzerland
| | - P S Morgan
- Medical Physics and Clinical Engineering (D.R., P.S.M.).,Nottingham Biomedical Research Centre of the UK National Institute of Health Research (P.S.M.), Nottingham, UK
| | - T Jaspan
- From Nottingham University Hospitals, Department of Radiology (T.J.)
| |
Collapse
|
12
|
Penault-Llorca F, Caux C, Depil S, Le Tourneau C, Pérol M, Robert C, Soumelis V, Couch D, Isambert N, Fernandez Y, Filleron T, Vassal G. CHECK'UP: A prospective cohort study to identify predictive factors of response and mechanisms of resistance to PD-1 and PD-L1 antagonists. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy493.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Vassal G, Cozic N, Houot R, Brugières L, Aparicio T, Blay JY, Perol M, Brice P, Meriaux E, Geoerger B, El Bejjani M, Moalla S, Bièche I, Lantuejoul S, Mahier Ait Oukhatar C, Hoog Labouret N, Moro-Sibilot D. Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSé program. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy279.421] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Gaspar N, Marshall LV, Binner D, Herold R, Rousseau R, Blanc P, Capdeville R, Carleer J, Copland C, Kerloeguen Y, Norga K, Pacaud L, Sevaux MA, Spadoni C, Sterba J, Ligas F, Taube T, Uttenreuther-Fischer M, Chioato S, O'Connell MA, Geoerger B, Blay JY, Soria JC, Kaye S, Wulff B, Brugières L, Vassal G, Pearson ADJ. Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE. Ann Oncol 2018; 29:766-771. [PMID: 29351570 PMCID: PMC5889024 DOI: 10.1093/annonc/mdy002] [Citation(s) in RCA: 51] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Affiliation(s)
- N Gaspar
- Department of Oncology for Children and Adolescents, Gustave Roussy Cancer Campus, Villejuif, France.
| | - L V Marshall
- Paediatric and Adolescent Drug Development Team, Oak Centre for Children & Young People, The Royal Marsden Hospital & The Institute of Cancer Research, London, UK
| | - D Binner
- Create for Chloe and UK Representative for aPODD, European Medicines Agency, London, UK
| | - R Herold
- Product Development Scientific Support Department, European Medicines Agency, London, UK
| | - R Rousseau
- Gritstone Oncology, Inc., Emeryville, USA
| | - P Blanc
- Imagine for Margo, Fourqueux, France
| | | | - J Carleer
- Belgium Federal Agency for Medicines and Health Products, EUROSTATION, Brussels, Belgium
| | - C Copland
- Centre for English Language Teaching, University of York, York, UK
| | - Y Kerloeguen
- Pharmaceuticals Division, PDOA, Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - K Norga
- Paediatric and Adolescent Drug Development Team, Oak Centre for Children & Young People, The Royal Marsden Hospital & The Institute of Cancer Research, London, UK; Universitair Ziekenhuis Antwerpen, Edegem, Belgium
| | | | | | - C Spadoni
- aPODD Foundation, City Point, London, UK
| | - J Sterba
- Pediatric Oncology Department, University Hospital Brno, School of Medicine Masaryk University Brno, Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, ICRC Brno, St. Anna University Hospital Brno, Czech Republic
| | - F Ligas
- Product Development Scientific Support Department, European Medicines Agency, London, UK
| | - T Taube
- Boehringer Ingelheim, Pharma GmbH&Co KG, TA Oncology, Biberach, Germany
| | | | - S Chioato
- Regulatory Strategy Oncology, Pfizer Italia, Milano, Italy
| | - M A O'Connell
- Regulatory Strategy Oncology, Pfizer Italia, Milano, Italy
| | - B Geoerger
- Department of Oncology for Children and Adolescents, Gustave Roussy Cancer Campus, Villejuif, France
| | - J-Y Blay
- Centre Léon Bérard and University Claude Bernard Lyon 1, Lyon
| | - J C Soria
- Drug Development Department (DITEP), Gustave Roussy, Villejuif and University Paris-Sud, Orsay, France
| | - S Kaye
- Adult Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, London, UK
| | - B Wulff
- Paediatric Haematology/Oncology, Clinical Research/Paediatric Drug Development, University Childreńs Hospital III Hufelandstraße, Essen, Germany
| | - L Brugières
- Department of Oncology for Children and Adolescents, Gustave Roussy Cancer Campus, Villejuif, France
| | - G Vassal
- Department of Clinical Research, Gustave Roussy, Villejuif and Paris-Sud University, Le Kremlin-Bicêtre, France
| | - A D J Pearson
- Paediatric and Adolescent Drug Development Team, Oak Centre for Children & Young People, The Royal Marsden Hospital & The Institute of Cancer Research, London, UK
| |
Collapse
|
15
|
Dumas A, Berger C, Auquier P, Michel G, Vassal G, Valteau-Couanet D, Fresneau B, Thouvenin-Doulet S, Casagranda L, Pacquement H, El-Fayech C, Oberlin O, Guibout C, De Vathaire F. Trajectoires scolaires après un cancer pédiatrique : une contribution à l’hypothèse de la sélection par la santé. Rev Epidemiol Sante Publique 2016. [DOI: 10.1016/j.respe.2015.07.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
16
|
Vassal G, Landman-Parker J, Baruchel A, Bergeron C, Rubie H, Coze C, Chastagner P, Leverger G, Bertrand Y, Valteau-Couanet D, Michon J, Couanet D, Rivière AM, Avenell D, Pérel Y, Doz F. Multidisciplinarité et formation des spécialistes à l’oncologie et à l’hématologie maligne pédiatrique. Arch Pediatr 2015; 22:1217-22. [DOI: 10.1016/j.arcped.2015.09.012] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2014] [Revised: 07/17/2015] [Accepted: 09/12/2015] [Indexed: 11/28/2022]
|
17
|
Vassal G, Schrappe M, Pritchard-Jones K, Arnold F, Basset L, Biondi A, Bode G, Eggert A, Hjorth L, Kamerić L, Karner S, Kearns P, Kienesberger A, Kowalczyk J, Lack P, Perilongo G, Sullivan R, Tsirou A, Kamerić N, Essiaf S, Ladenstein R. 1407 The European Strategic Plan for children and adolescents with cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30578-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
18
|
Vassal G, Moro-sibilot D, Le Deley M, Hoog-labouret N, Nowak F, Jimenez M, Tournigand C, Houot R, Malka D, Aparicio T, Escudier B, Ray-coquard I, Godbert Y, Taillandier L, Bieche I, Lantuejoul S, Ferretti G, Menu Y, Blay J, Buzyn A. 12LBA Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSe Program. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(15)30070-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
19
|
Karayan-Tapon L, Cortes U, Rivet P, Jermidi C, Vassal G, Wager M, Taillandier L. Lack of GOPC-ROS1 (FIG-ROS1) rearrangement in adult human gliomas. Eur J Cancer 2014; 50:2364-6. [DOI: 10.1016/j.ejca.2014.06.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2014] [Revised: 05/27/2014] [Accepted: 06/02/2014] [Indexed: 11/30/2022]
|
20
|
Grill J, Hargrave D, Varlet P, Jaspan T, Jones C, Massimino M, Cañete A, Azizi A, Le Deley M, Saran F, Morgan P, Zahlmann G, Zheng M, Fuerst-Recktenwald S, Berger C, Bouffet E, Vassal G. The Herby Study: a Phase 2 Open-Label, Randomized, Multicenter Study of Bevacizumab-Based Therapy in Pediatric Patients with Newly Diagnosed High-Grade Glioma. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu330.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Classen CF, William D, Linnebacher M, Farhod A, Kedr W, Elsabe B, Fadel S, Van Gool S, De Vleeschouwer S, Koks C, Garg A, Ehrhardt M, Riva M, De Vleeschouwer S, Agostinis P, Graf N, Van Gool S, Yao TW, Yoshida Y, Zhang J, Ozawa T, James D, Nicolaides T, Kebudi R, Cakir FB, Gorgun O, Agaoglu FY, Darendeliler E, Van Gool S, De Vleeschouwer S, Al-Kofide A, Al-Shail E, Khafaga Y, Al-Hindi H, Dababo M, Haq AU, Anas M, Barria MG, Siddiqui K, Hassounah M, Ayas M, van Zanten SV, Jansen M, van Vuurden D, Huisman M, Vugts D, Hoekstra O, van Dongen G, Kaspers G, Cockle J, Ilett E, Scott K, Bruning-Richardson A, Picton S, Short S, Melcher A, Benesch M, Warmuth-Metz M, von Bueren AO, Hoffmann M, Pietsch T, Kortmann RD, Eyrich M, Graf N, Rutkowski S, Fruhwald MC, Faber J, Kramm C, Porkholm M, Valanne L, Lonnqvist T, Holm S, Lannering B, Riikonen P, Wojcik D, Sehested A, Clausen N, Harila-Saari A, Schomerus E, Thorarinsdottir HK, Lahteenmaki P, Arola M, Thomassen H, Saarinen-Pihkala UM, Kivivuori SM, Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Morrison A, Bouffet E, Bartels U, Becher O, Hawkins C, Gould TWA, Rahman CV, Smith SJ, Barrett DA, Shakesheff KM, Grundy RG, Rahman R, Barua N, Cronin D, Gill S, Lowisl S, Hochart A, Maurage CA, Rocourt N, Vinchon M, Kerdraon O, Escande F, Grill J, Pick VK, Leblond P, Burzynski G, Janicki T, Burzynski S, Marszalek A, Ramani N, Zaky W, Kannan G, Morani A, Sandberg D, Ketonen L, Maher O, Corrales-Medina F, Meador H, Khatua S, Brassesco M, Delsin L, Roberto G, Silva C, Ana L, Rego E, Scrideli C, Umezawa K, Tone L, Kim SJ, Kim CY, Kim IA, Han JH, Choi BS, Ahn HS, Choi HS, Haque F, Rahman R, Layfield R, Grundy R, Gandola L, Pecori E, Biassoni V, Schiavello E, Chiruzzi C, Spreafico F, Modena P, Bach F, Pignoli E, Massimino M, Drogosiewicz M, Dembowska-Baginska B, Jurkiewicz E, Filipek I, Perek-Polnik M, Swieszkowska E, Perek D, Bender S, Jones DT, Warnatz HJ, Hutter B, Zichner T, Gronych J, Korshunov A, Eils R, Korbel JO, Yaspo ML, Lichter P, Pfister SM, Yadavilli S, Becher OJ, Kambhampati M, Packer RJ, Nazarian J, Lechon FC, Fowkes L, Khabra K, Martin-Retortillo LM, Marshall LV, Vaidya S, Koh DM, Leach MO, Pearson AD, Zacharoulis S, Lechon FC, Fowkes L, Khabra K, Martin-Retortillo LM, Marshall LV, Schrey D, Barone G, Vaidya S, Koh DM, Pearson AD, Zacharoulis S, Panditharatna E, Stampar M, Siu A, Gordish-Dressman H, Devaney J, Kambhampati M, Hwang EI, Packer RJ, Nazarian J, Chung AH, Mittapalli RK, Elmquist WF, Becher OJ, Castel D, Debily MA, Philippe C, Truffaux N, Taylor K, Calmon R, Boddaert N, Le Dret L, Saulnier P, Lacroix L, Mackay A, Jones C, Puget S, Sainte-Rose C, Blauwblomme T, Varlet P, Grill J, Entz-Werle N, Maugard C, Bougeard G, Nguyen A, Chenard MP, Schneider A, Gaub MP, Tsoli M, Vanniasinghe A, Luk P, Dilda P, Haber M, Hogg P, Ziegler D, Simon S, Tsoli M, Vanniasinghe A, Monje M, Gurova K, Gudkov A, Haber M, Ziegler D, Zapotocky M, Churackova M, Malinova B, Zamecnik J, Kyncl M, Tichy M, Puchmajerova A, Stary J, Sumerauer D, Boult J, Vinci M, Taylor K, Perryman L, Box G, Jury A, Popov S, Ingram W, Monje M, Eccles S, Jones C, Robinson S, Emir S, Demir HA, Bayram C, Cetindag F, Kabacam GB, Fettah A, Boult J, Li J, Vinci M, Jury A, Popov S, Jamin Y, Cummings C, Eccles S, Bamber J, Sinkus R, Jones C, Robinson S, Nandhabalan M, Bjerke L, Vinci M, Burford A, Ingram W, Mackay A, von Bueren A, Baudis M, Clarke P, Collins I, Workman P, Jones C, Taylor K, Mackay A, Vinci M, Popov S, Ingram W, Entz-Werle N, Monje M, Olaciregui N, Mora J, Carcaboso A, Bullock A, Jones C, Vinci M, Mackay A, Burford A, Taylor K, Popov S, Ingram W, Monje M, Alonso M, Olaciregui N, de Torres C, Cruz O, Mora J, Carcaboso A, Jones C, Filipek I, Drogosiewicz M, Perek-Polnik M, Swieszkowska E, Dembowska-Baginska B, Jurkiewicz E, Perek D, Nguyen A, Pencreach E, Mackay A, Moussalieh FM, Guenot D, Namer I, Chenard MP, Jones C, Entz-Werle N, Pollack I, Jakacki R, Butterfield L, Hamilton R, Panigrahy A, Potter D, Connelly A, Dibridge S, Whiteside T, Okada H, Ahsan S, Raabe E, Haffner M, Warren K, Quezado M, Ballester L, Nazarian J, Eberhart C, Rodriguez F, Ramachandran C, Nair S, Quirrin KW, Khatib Z, Escalon E, Melnick S, Classen CF, Hofmann M, Schmid I, Simon T, Maass E, Russo A, Fleischhack G, Becker M, Hauch H, Sander A, Kramm C, Grasso C, Truffaux N, Berlow N, Liu L, Debily MA, Davis L, Huang E, Woo P, Tang Y, Ponnuswami A, Chen S, Huang Y, Hutt-Cabezas M, Warren K, Dret L, Meltzer P, Mao H, Quezado M, van Vuurden D, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Raabe E, Hulleman E, Li XN, Keller C, Spellman PT, Pal R, Grill J, Monje M, Jansen MHA, Sewing ACP, Lagerweij T, Vuchts DJ, van Vuurden DG, Caretti V, Wesseling P, Kaspers GJL, Hulleman E, Cohen K, Raabe E, Pearl M, Kogiso M, Zhang L, Qi L, Lindsay H, Lin F, Berg S, Li XN, Muscal J, Amayiri N, Tabori U, Campbel B, Bakry D, Aronson M, Durno C, Gallinger S, Malkin D, Qaddumi I, Musharbash A, Swaidan M, Bouffet E, Hawkins C, Al-Hussaini M, Rakopoulos P, Shandilya S, McCully C, Murphy R, Akshintala S, Cole D, Macallister RP, Cruz R, Widemann B, Warren K, Salloum R, Smith A, Glaunert M, Ramkissoon A, Peterson S, Baker S, Chow L, Sandgren J, Pfeifer S, Popova S, Alafuzoff I, de Stahl TD, Pietschmann S, Kerber MJ, Zwiener I, Henke G, Kortmann RD, Muller K, von Bueren A, Sieow NYF, Hoe RHM, Tan AM, Chan MY, Soh SY, Hawkins C, Burrell K, Chornenkyy Y, Remke M, Golbourn B, Buczkowicz P, Barzczyk M, Taylor M, Rutka J, Dirks P, Zadeh G, Agnihotri S, Hashizume R, Ihara Y, Andor N, Chen X, Lerner R, Huang X, Tom M, Solomon D, Mueller S, Petritsch C, Zhang Z, Gupta N, Waldman T, James D, Dujua A, Co J, Hernandez F, Doromal D, Hegde M, Wakefield A, Brawley V, Grada Z, Byrd T, Chow K, Krebs S, Heslop H, Gottschalk S, Yvon E, Ahmed N, Truffaux N, Philippe C, Cornilleau G, Paulsson J, Andreiuolo F, Guerrini-Rousseau L, Puget S, Geoerger B, Vassal G, Ostman A, Grill J, Parsons DW, Lin F, Trevino LR, Gao F, Shen X, Hampton O, Lindsay H, Kosigo M, Qi L, Baxter PA, Su JM, Chintagumpala M, Dauser R, Adesina A, Plon SE, Li XN, Wheeler DA, Lau CC, Pietsch T, Gielen G, Muehlen AZ, Kwiecien R, Wolff J, Kramm C, Lulla RR, Laskowski J, Goldman S, Gopalakrishnan V, Fangusaro J, Mackay A, Taylor K, Vinci M, Jones C, Kieran M, Fontebasso A, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, Bechet D, Faury D, De Jay N, Ramkissoon L, Corcoran A, Jones D, Sturm D, Johann P, Tomita T, Goldman S, Nagib M, Bendel A, Goumnerova L, Bowers DC, Leonard JR, Rubin JB, Alden T, DiPatri A, Browd S, Leary S, Jallo G, Cohen K, Prados MD, Banerjee A, Carret AS, Ellezam B, Crevier L, Klekner A, Bognar L, Hauser P, Garami M, Myseros J, Dong Z, Siegel PM, Gump W, Ayyanar K, Ragheb J, Khatib Z, Krieger M, Kiehna E, Robison N, Harter D, Gardner S, Handler M, Foreman N, Brahma B, MacDonald T, Malkin H, Chi S, Manley P, Bandopadhayay P, Greenspan L, Ligon A, Albrecht S, Pfister SM, Ligon KL, Majewski J, Gupta N, Jabado N, Hoeman C, Cordero F, Halvorson K, Hawkins C, Becher O, Taylor I, Hutt M, Weingart M, Price A, Nazarian J, Eberhart C, Raabe E, Kantar M, Onen S, Kamer S, Turhan T, Kitis O, Ertan Y, Cetingul N, Anacak Y, Akalin T, Ersahin Y, Mason G, Nazarian J, Ho C, Devaney J, Stampar M, Kambhampati M, Crozier F, Vezina G, Packer R, Hwang E, Gilheeney S, Millard N, DeBraganca K, Khakoo Y, Kramer K, Wolden S, Donzelli M, Fischer C, Petriccione M, Dunkel I, Afzal S, Carret AS, Fleming A, Larouche V, Zelcer S, Johnston DL, Kostova M, Mpofu C, Decarie JC, Strother D, Lafay-Cousin L, Eisenstat D, Fryer C, Hukin J, Bartels U, Bouffet E, Hsu M, Lasky J, Moore T, Liau L, Davidson T, Prins R, Fouladi M, Bartels U, Warren K, Hassal T, Baugh J, Kirkendall J, Doughman R, Leach J, Jones B, Miles L, Hawkins C, Bouffet E, Hargrave D, Grill J, Jones C, Jacques T, Savage S, Goldman S, Leary S, Packer R, Saunders D, Wesseling P, Varlet P, van Vuurden D, Wallace R, Flutter B, Morgenestern D, Hargrave D, Blanco E, Howe K, Lowdell M, Samuel E, Michalski A, Anderson J, Arakawa Y, Umeda K, Watanabe KI, Mizowaki T, Hiraoka M, Hiramatsu H, Adachi S, Kunieda T, Takagi Y, Miyamoto S, Venneti S, Santi M, Felicella MM, Sullivan LM, Dolgalev I, Martinez D, Perry A, Lewis PW, Allis DC, Thompson CB, Judkins AR. HIGH GRADE GLIOMAS AND DIPG. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Antony R, Zagardo M, Gujrati M, Lin J, Antony R, Al-Rahawan M, Zagardo M, Gujrati M, Lin J, Broniscer A, Bhardwaj R, Hampton C, Ozols V, Chakravadhanula M, Bouffet E, Hawkins C, Scheinemann K, Zelcer S, Johnston D, Lafay-Cousin L, Larouche V, Jabado N, Carret AS, Hukin J, Eisenstat D, Pond G, Poskitt K, Wilson B, Bartels U, Tabori U, Dhall G, Haley K, Finlay J, Rushing T, Sposto R, Seeger R, Garvin J, Rupani K, Stark E, Anderson R, Feldstein N, Grill J, Hargrave D, Massimino M, Jaspan T, Varlet P, Jones C, Morgan P, Le Deley MC, Azizi A, Canete A, Bouffet E, Saran F, Bachir J, Bubuteishvili-Pacaud L, Rousseau R, Vassal G, Gupta S, Robinson N, Dhir N, Wong K, Zhou S, Finlay J, Dhall G, Kumabe T, Kawaguchi T, Saito R, Kanamori M, Yamashita Y, Sonoda Y, Tominaga T, Miyagawa T, Nwachukwu C, Youland R, Laack N, Filipek I, Drogosiewicz M, Polnik MP, Swieszkowska E, Dembowska-Baginska B, Jurkiewicz E, Perek D, Perek D, Dembowska-Baginska B, Drogosiewicz M, Polnik MP, Grajkowska W, Roszkowski M, Sobol G, Musiol K, Wachowiak J, Kazmierczak B, Pogorzelski JP, Mlynarski W, Szewczyk BZ, Wysocki M, Niedzielska E, Kowalczyk J, Slusarz HW, Balwierz W, Czepko EZ, Szolkiewicz A, Perek D, Perek-Polnik M, Dembowska-Baginska B, Drogosiewicz M, Grajkowska W, Lastowska M, Chojnacka M, Filipek I, Tarasinska M, Roszkowski M, Perreault S, Chao K, Ramaswamy V, Shih D, Remke M, Luu B, Schubert S, Fisher P, Partap S, Vogel H, Taylor M, Goumnerova L, Cho YJ, Robison N, Dhall G, Brown R, Cloughesy T, Davidson TB, Krieger M, Berger M, Wong K, Perry A, Gilles F, Finlay JL, Robison N, Dhir N, Khemani J, Wong K, Gupta S, Britt B, Grimm J, Finlay J, Dhall G, Ruge MI, Blau T, Hafkemeyer V, Hamisch C, Klinger K, Simon T, Sadighi Z, Ellezam B, Guindani M, Ater J, Shimizu Y, Arai H, Miyajima M, Shimoji K, Kondo A, Shinohara E, Perkins S, DeWees T, Slavc I, Chocholous M, Leiss U, Haberler C, Peyrl A, Azizi AA, Dieckmann K, Woehrer A, Dorfer C, Czech T, Spence T, Picard D, Barszczyk M, Kim SK, Ra YS, Fangusaro J, Toledano H, Nakamura H, Lafay-Cousin L, Fan X, Muraszko KM, Ng HK, Bouffet E, Halliday W, Shago M, Hawkins CE, Huang A, Suzuki M, Kondo A, Miyajima M, Arai H, van Zanten SV, Jansen M, van Vuurden D, Hulleman E, Idema S, Noske D, Wolf N, Hendrikse H, Vandertop P, Kaspers GJ, Muller K, Schlamann A, Warmuth-Metz M, Pietsch T, Pietschmann S, Kortmann RD, Kramm CM, von Bueren AO, Walston S, Williams T, Hamstra D, Oh K, Pelloski C, Zhukova N, Pole J, Mistry M, Fried I, Bartels U, Huang A, Lapperiere N, Dirks P, Scheinemann K, An J, Alon N, Nathan P, Greenberg M, Bouffet E, Malkin D, Hawkins C, Tabori U. PEDIATRICS CLINICAL RESEARCH. Neuro Oncol 2013; 15:iii165-iii172. [PMCID: PMC3823900 DOI: 10.1093/neuonc/not185] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/01/2023] Open
|
23
|
Truffaux N, Puget S, Vassal G, Geoerger B, Grill J. 347 Efficacy of Dasatinib in Targeting Diffuse Intrinsic Pontine Glioma (DIPG) Specific Pathway Activation in Vitro. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72145-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
24
|
Daudigeos-Dubus E, Le Dret L, Philippe C, Andreiuolo F, Bawa O, Pata-Merci N, Munier F, Vassal G, Geoerger B. 205 Development of Metastasis Following Inhibition of VEGFR Pathway in an Orthotopic Neuroblastoma Model. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72003-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
25
|
Lanvers-Kaminsky C, Abbou S, Daudigeos-Dubus E, Molenaar J, Verschuur A, Caron H, Vassal G, Geoerger B. 253 Anti-tumor Activity of the PLK Inhibitor Volasertib (BI 6727) and the Aurora Kinase Inhibitor BI 811283 in Pediatric Malignancies. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72051-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
26
|
Veal G, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-Couanet D, Brock P, Ladenstein R, Vassal G. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. Eur J Cancer 2012; 48:3063-72. [DOI: 10.1016/j.ejca.2012.05.020] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2012] [Revised: 04/30/2012] [Accepted: 05/22/2012] [Indexed: 01/08/2023]
|
27
|
Ladenstein R, Vassal G, Pritchard-Jones K, Schrappe M. 171 INVITED The European Network for Cancer Research in Children and Adolescents(ENCCA) FP7 Project. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70386-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
28
|
Grill J, Puget S, Philippe C, Vassal G. 199 INVITED Are Adult and Paediatric High Grade Gliomas the Same – Insight From Biology and Molecular Pathology. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70414-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
29
|
Puget S, Philippe C, Job B, Varlet P, Andreiuolo F, Roujeau T, Richon C, Doz F, Zerah M, Blauwblomme T, Sainte-Rose C, Vassal G, Grill J. La biologie moléculaire des gliomes infiltrants du tronc de l’enfant : vers une thérapeutique ciblée ? Neurochirurgie 2011. [DOI: 10.1016/j.neuchi.2011.09.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
30
|
Berghtold G, Dantas Barbosa C, Dieffenbach G, Daudigeos-Dubus E, Blokus H, Ferreira C, Boylan J, Abely M, Vassal G, Grill J, Geoerger B. NOTCH1 inhibition by the gamma-secretase inhibitor RO4929097 in pediatric glial tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.9555] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Beaugrand A, Lanvers-Kaminsky C, Aviles Marin PM, Cuevas Marchante C, Opolon P, Le Dret L, Verschuur A, Vassal G, Geoerger B. Cell cycle and apoptotic effects of PM00104 in pediatric cell lines and xenographs. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.9546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
32
|
Pritchard-Jones K, Lewison G, Camporesi S, Vassal G, Ladenstein R, Benoit Y, Predojevic JS, Sterba J, Stary J, Eckschlager T, Schroeder H, Doz F, Creutzig U, Klingebiel T, Kosmidis HV, Garami M, Pieters R, O'Meara A, Dini G, Riccardi R, Rascon J, Rageliene L, Calvagna V, Czauderna P, Kowalczyk JR, Gil-da-Costa MJ, Norton L, Pereira F, Janic D, Puskacova J, Jazbec J, Canete A, Hjorth L, Ljungman G, Kutluk T, Morland B, Stevens M, Walker D, Sullivan R. The state of research into children with cancer across Europe: new policies for a new decade. Ecancermedicalscience 2011; 5:210. [PMID: 22276053 PMCID: PMC3223943 DOI: 10.3332/ecancer.2011.210] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2011] [Indexed: 11/12/2022] Open
Abstract
Overcoming childhood cancers is critically dependent on the state of research. Understanding how, with whom and what the research community is doing with childhood cancers is essential for ensuring the evidence-based policies at national and European level to support children, their families and researchers. As part of the European Union funded EUROCANCERCOMS project to study and integrate cancer communications across Europe, we have carried out new research into the state of research in childhood cancers. We are very grateful for all the support we have received from colleagues in the European paediatric oncology community, and in particular from Edel Fitzgerald and Samira Essiaf from the SIOP Europe office. This report and the evidence-based policies that arise from it come at a important junction for Europe and its Member States. They provide a timely reminder that research into childhood cancers is critical and needs sustainable long-term support.
Collapse
|
33
|
Geoerger B, Vassal G. Innovative Therapies for Children with Cancer (ITCC): Clinical Trial Program. Klin Padiatr 2010. [DOI: 10.1055/s-0030-1270318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
34
|
Molenaar JJ, Westerhout EM, Den Boer ML, Clifford SC, Delattre O, Geoerger B, Lanvers C, Pietsch T, Serra M, Shipley J, Vassal G, Versteeg R, Verschuur AC, Caron HN. The KidsCancerKinome: Validation of Cell Cycle Genes as Potential Drug Targets in Pediatric Tumors. Klin Padiatr 2010. [DOI: 10.1055/s-0030-1270311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
Caron HN, Westerhout EM, Kool M, Molenaar JJ, Stroeken PJ, Den Boer M, Segers S, Clifford S, Delattre O, Geoerger B, Benetkiewicz M, Lanvers C, Warps R, Pieters R, Pietsch T, Holst M, Renshaw J, Serra M, Scotlandi K, Shipley J, Vassal G, Degrand O, Verschuur AC, Versteeg R. The KidsCancerKinome - Validation of Drug Targets for High Risk Childhood Cancers. Klin Padiatr 2010. [DOI: 10.1055/s-0030-1270317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
36
|
Duclos J, Valent A, Malouf G, Drusch F, Auger N, Vielh P, Vassal G, Duvillard P, Pautier P. Immunohistochemical study and fluorescent in situ hybridization analysis of JAZF1 in 67 cases of endometrial stromal tumors collected in a tissue microarray. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Puget S, Philippe C, De Carli E, Grundy R, Job B, Varlet P, Richon C, Sainte-Rose C, Vassal G, Grill J. Use of integrated genomics to identify three high-grade glioma subtypes with distinct genetic profiles, pathway signatures, and clinicopathologic features. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e12500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Alsafadi S, Tourpin S, Andre F, Vassal G, Ahomadegbe JC. P53 Family: At the Crossroads in Cancer Therapy. Curr Med Chem 2009; 16:4328-44. [DOI: 10.2174/092986709789578196] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2009] [Accepted: 09/20/2009] [Indexed: 11/22/2022]
|
39
|
Vassal G. 82 How to select a new drug in paediatric oncology. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)70078-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
40
|
Geoerger B, Hargrave D, Thomas F, Andreiuolo F, Varlet P, Frappaz D, Doz F, Riccardi R, Jaspan T, Vassal G. Pharmacokinetic and biological study of erlotinib in children as monotherapy for refractory brain tumors or with radiation for newly diagnosed brain stem gliomas. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10019 Background: This multicenter phase I study was designed to determine the recommended dose (RD) of erlotinib, a small-molecule EGFR TKI, in patients ≤ 21 years as monotherapy or in combination with radiation therapy (RT). Methods: Group 1 included patients with brain tumors refractory to or relapsing after conventional therapy; receiving erlotinib alone. Group 2 included newly diagnosed patients with brain stem gliomas, who received RT (54Gy) and erlotinib. Conventional 3+3 dose escalation was used for Group 1; a continual reassessment method for Group 2. Four dose levels were planned: 75, 100, 125 and 150 mg/m2/day. Results: A total of 51 patients were enrolled (30 in Group 1; 21 in Group 2); 50 received treatment. Median age was 10 and 6 years, respectively. The RD of erlotinib was 125 mg/m2/day as monotherapy or in combination with RT. 203 adverse events in 44 patients were possibly treatment-related; 188 were G1/2; 9 G3, 2 G4, and 4 G5. Dermatologic and neurologic symptoms were most common; intratumoral hemorrhage was noted in 4 patients. In Group 1, 8 patients (27.6%) had stable disease, 2 with 45% tumor regression. In Group 2, 3 patients (14%) had partial response and 8 (38%) were stabilized; median OS was 12 months. Pharmacokinetic data of 46 patients were analyzed; patients’ weight and erlotinib clearance (CL) were significantly correlated. Mean (± SD) apparent CL and volume of distribution for erlotinib were 143.7 mL/h/kg (± 66.3) and 3.5 L/kg (± 3.0), respectively, and were independent of dose level. Mean half-life for erlotinib was 20.4 hours. Biomarker analyses on archived tumor or biopsy tissue prior to study entry for newly diagnosed brain stem glioma found 18/37 tumors tested were EGFR IHC+; 16/37 and 23/36 were pAKT+ and pMAPK+, respectively. High EGFR expression was more common in supratentorial gliomas; PTEN loss was most common in brain stem glioma (15/19) and was not observed in ependymomas. Conclusions: Erlotinib 125 mg/m2/day has an acceptable tolerability profile in pediatric patients with brain tumors, and can be safely combined with RT. Further studies are required to define the efficacy of this treatment approach and to establish the impact of biomarkers on outcomes in pediatric glial tumors. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. Geoerger
- Institut Gustave Roussy, Villejuif, France; Royal Marsden Hospital, Sutton, United Kingdom; Institut Claudius Regaud, Toulouse, France; Sainte-Anne Hospital, University of Paris, Paris, France; Institut d'Hématologie-Oncologie Pédiatrique, Lyon, France; Institut Curie, Paris, France; Catholic University of Rome, Rome, Italy; University Hospital Nottingham, Nottingham, United Kingdom
| | - D. Hargrave
- Institut Gustave Roussy, Villejuif, France; Royal Marsden Hospital, Sutton, United Kingdom; Institut Claudius Regaud, Toulouse, France; Sainte-Anne Hospital, University of Paris, Paris, France; Institut d'Hématologie-Oncologie Pédiatrique, Lyon, France; Institut Curie, Paris, France; Catholic University of Rome, Rome, Italy; University Hospital Nottingham, Nottingham, United Kingdom
| | - F. Thomas
- Institut Gustave Roussy, Villejuif, France; Royal Marsden Hospital, Sutton, United Kingdom; Institut Claudius Regaud, Toulouse, France; Sainte-Anne Hospital, University of Paris, Paris, France; Institut d'Hématologie-Oncologie Pédiatrique, Lyon, France; Institut Curie, Paris, France; Catholic University of Rome, Rome, Italy; University Hospital Nottingham, Nottingham, United Kingdom
| | - F. Andreiuolo
- Institut Gustave Roussy, Villejuif, France; Royal Marsden Hospital, Sutton, United Kingdom; Institut Claudius Regaud, Toulouse, France; Sainte-Anne Hospital, University of Paris, Paris, France; Institut d'Hématologie-Oncologie Pédiatrique, Lyon, France; Institut Curie, Paris, France; Catholic University of Rome, Rome, Italy; University Hospital Nottingham, Nottingham, United Kingdom
| | - P. Varlet
- Institut Gustave Roussy, Villejuif, France; Royal Marsden Hospital, Sutton, United Kingdom; Institut Claudius Regaud, Toulouse, France; Sainte-Anne Hospital, University of Paris, Paris, France; Institut d'Hématologie-Oncologie Pédiatrique, Lyon, France; Institut Curie, Paris, France; Catholic University of Rome, Rome, Italy; University Hospital Nottingham, Nottingham, United Kingdom
| | - D. Frappaz
- Institut Gustave Roussy, Villejuif, France; Royal Marsden Hospital, Sutton, United Kingdom; Institut Claudius Regaud, Toulouse, France; Sainte-Anne Hospital, University of Paris, Paris, France; Institut d'Hématologie-Oncologie Pédiatrique, Lyon, France; Institut Curie, Paris, France; Catholic University of Rome, Rome, Italy; University Hospital Nottingham, Nottingham, United Kingdom
| | - F. Doz
- Institut Gustave Roussy, Villejuif, France; Royal Marsden Hospital, Sutton, United Kingdom; Institut Claudius Regaud, Toulouse, France; Sainte-Anne Hospital, University of Paris, Paris, France; Institut d'Hématologie-Oncologie Pédiatrique, Lyon, France; Institut Curie, Paris, France; Catholic University of Rome, Rome, Italy; University Hospital Nottingham, Nottingham, United Kingdom
| | - R. Riccardi
- Institut Gustave Roussy, Villejuif, France; Royal Marsden Hospital, Sutton, United Kingdom; Institut Claudius Regaud, Toulouse, France; Sainte-Anne Hospital, University of Paris, Paris, France; Institut d'Hématologie-Oncologie Pédiatrique, Lyon, France; Institut Curie, Paris, France; Catholic University of Rome, Rome, Italy; University Hospital Nottingham, Nottingham, United Kingdom
| | - T. Jaspan
- Institut Gustave Roussy, Villejuif, France; Royal Marsden Hospital, Sutton, United Kingdom; Institut Claudius Regaud, Toulouse, France; Sainte-Anne Hospital, University of Paris, Paris, France; Institut d'Hématologie-Oncologie Pédiatrique, Lyon, France; Institut Curie, Paris, France; Catholic University of Rome, Rome, Italy; University Hospital Nottingham, Nottingham, United Kingdom
| | - G. Vassal
- Institut Gustave Roussy, Villejuif, France; Royal Marsden Hospital, Sutton, United Kingdom; Institut Claudius Regaud, Toulouse, France; Sainte-Anne Hospital, University of Paris, Paris, France; Institut d'Hématologie-Oncologie Pédiatrique, Lyon, France; Institut Curie, Paris, France; Catholic University of Rome, Rome, Italy; University Hospital Nottingham, Nottingham, United Kingdom
| |
Collapse
|
41
|
Patel S, Pappo A, Crowley J, Reinke D, Eid J, Ritland S, Chawla S, Staddon A, Maki R, Vassal G, Helman L. A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10503] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10503 Background: The IGF1 system has been implicated in sarcoma development and inhibition of IGF1R function has been shown to induce clinical responses in select sarcomas. Methods: Objectives included response rate (RR) and progression-free survival (PFS) to R1507 in patients with recurrent or refractory Ewing's (ES, 2 cohorts- primary refractory vs. others) osteo (OS), synovial (SS), rhabdomyosarcoma (RMS), and other sarcomas. Eligibility included recurrent/refractory measurable disease, age ≥ 12 yrs, life expectancy ≥ 6 weeks, Karnofsky PS ≥ 70, adequate renal, hepatic and bone marrow function. R1507 was administered i.v. at 9 mg/kg over one hour weekly. Response was assessed by WHO criteria every 6 wks X 4 and every 12 wks thereafter. A two-stage design (Green and Dahlberg) was used. The endpoint for the primary refractory ES cohort was PFS at week 18 (planned n=65). RR was the primary endpoint for the remaining cohorts (planned n=240). Results: From 12/07–12/08, 203 eligible patients from 29 centers across the US, Europe and Australia were enrolled. Age ranged from 12–85 yrs (median=27 yrs) and 126 were male. Verified histologic subtypes were ES (n=71), OS (n=43), RMS (n=28), SS (n=25), and others (n=25). 15 severe adverse events were reported in 9 patients, the most common being fatigue (n=2), thrombocytopenia (n=2), dehydration (n=2), and hyperglycemia (n=2). Clinically significant activity has been observed in ES, RMS and OS with several dramatic responses seen in ES and RMS. Independent radiologic review is currently ongoing and updated data will be presented. Conclusions: The rapid accrual amongst many centers in diverse geographical locations demonstrates the feasibility of collaborative research in sarcomas. R1507 is well tolerated and a promising new agent for the treatment of various sarcomas. SARC and Roche are collaborating in additional clinical trials to better define the role of R1507 in the treatment of selected sarcomas. [Table: see text]
Collapse
Affiliation(s)
- S. Patel
- Sarcoma Alliance for Research and Collaboration, Ann Arbor, MI; Hoffman-La Roche, Nutley, NJ
| | - A. Pappo
- Sarcoma Alliance for Research and Collaboration, Ann Arbor, MI; Hoffman-La Roche, Nutley, NJ
| | - J. Crowley
- Sarcoma Alliance for Research and Collaboration, Ann Arbor, MI; Hoffman-La Roche, Nutley, NJ
| | - D. Reinke
- Sarcoma Alliance for Research and Collaboration, Ann Arbor, MI; Hoffman-La Roche, Nutley, NJ
| | - J. Eid
- Sarcoma Alliance for Research and Collaboration, Ann Arbor, MI; Hoffman-La Roche, Nutley, NJ
| | - S. Ritland
- Sarcoma Alliance for Research and Collaboration, Ann Arbor, MI; Hoffman-La Roche, Nutley, NJ
| | - S. Chawla
- Sarcoma Alliance for Research and Collaboration, Ann Arbor, MI; Hoffman-La Roche, Nutley, NJ
| | - A. Staddon
- Sarcoma Alliance for Research and Collaboration, Ann Arbor, MI; Hoffman-La Roche, Nutley, NJ
| | - R. Maki
- Sarcoma Alliance for Research and Collaboration, Ann Arbor, MI; Hoffman-La Roche, Nutley, NJ
| | - G. Vassal
- Sarcoma Alliance for Research and Collaboration, Ann Arbor, MI; Hoffman-La Roche, Nutley, NJ
| | - L. Helman
- Sarcoma Alliance for Research and Collaboration, Ann Arbor, MI; Hoffman-La Roche, Nutley, NJ
| |
Collapse
|
42
|
Sartelet H, Haddad E, Imbriglio T, Arsenault M, Ohta S, Barrette S, Sinnett D, Laverdiere C, Oligny L, Vassal G. Expression of CD133 and poor outcome in neuroblastoma associated with chemoresistance mediated by AKT pathway. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10007 Background: Neuroblastoma is a frequent childhood cancer with very heterogeneous prognosis. Recent studies showed that CD133 expression is an independent prognostic marker for low survival in several cancers like medulloblastoma. The aim of our study is to determine the prognostic value of CD133 expression in a large population of neuroblastoma and to determine the chemoresistance of neuroblasts expressing CD133. Methods: 280 tumor samples of neuroblastoma were screened for CD133 expression. Patients had a median follow-up of 7.15 years. One hundred eighteen patients were under one year of age with a median age of 27 months. There were 67 stage 1, 46 stage 2, 43 stage 3, 99 stage 4, and 25 stage 4S. The association of CD133 expression with relapse and survival were determined through univariate and multivariate analysis. Sensitivity of purified CD133+ neuroblasts isolated from 2 human neuroblastoma cell lines (SKNSH and NB10) to doxorubicin, vincristine and cisplatin was evaluated in vitro, as single agents or in combination with LY294002, a AKT inhibitor. Results: CD133 was expressed in 95 of 280 tumors (33%). There was a significant association between CD133 expression and the following poor prognosis co-variates: age (p<0.0001), INSS stage (p<0.0001), MYCN amplification (p<0.0001). Patients with a CD133+ tumor had a three year event-free and overall survival of 43±5% and 51±5%, respectively, as compared to patients with a CD133- tumor with 88±2% (P<0.001) and 95±2% (p<0.001). In a multivariate model, CD133 expression was independently associated with a decreased overall survival (p = 0.003) in the entire cohort. In vitro purified CD133+ neuroblasts were significantly resistant to chemotherapy as compared to their CD133- cells counterpart, but not in presence of the AKT inhibitor. In vitro treatment of unsorted neuroblasts with the three anticancer drugs significantly enriched the CD133+ subpopulation but not in presence of the AKT inhibitor. CD133plus; significantly expressed higher levels of activated proteins in the AKT pathway than CD133−. Conclusions: CD133 is independently associated with a worse outcome in patents with neuroblastoma. This prognosis factor is associated with in vitro resistance to chemotherapy involving activation of the AKT pathway. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. Sartelet
- Sainte Justine Hospital, Montreal, QC, Canada; CHU Sainte Justine, Montreal, QC, Canada; Shiga University of Medical Sceince, Otsu, Ireland; Insitut Gustave Roussy, Villejuif, France
| | - E. Haddad
- Sainte Justine Hospital, Montreal, QC, Canada; CHU Sainte Justine, Montreal, QC, Canada; Shiga University of Medical Sceince, Otsu, Ireland; Insitut Gustave Roussy, Villejuif, France
| | - T. Imbriglio
- Sainte Justine Hospital, Montreal, QC, Canada; CHU Sainte Justine, Montreal, QC, Canada; Shiga University of Medical Sceince, Otsu, Ireland; Insitut Gustave Roussy, Villejuif, France
| | - M. Arsenault
- Sainte Justine Hospital, Montreal, QC, Canada; CHU Sainte Justine, Montreal, QC, Canada; Shiga University of Medical Sceince, Otsu, Ireland; Insitut Gustave Roussy, Villejuif, France
| | - S. Ohta
- Sainte Justine Hospital, Montreal, QC, Canada; CHU Sainte Justine, Montreal, QC, Canada; Shiga University of Medical Sceince, Otsu, Ireland; Insitut Gustave Roussy, Villejuif, France
| | - S. Barrette
- Sainte Justine Hospital, Montreal, QC, Canada; CHU Sainte Justine, Montreal, QC, Canada; Shiga University of Medical Sceince, Otsu, Ireland; Insitut Gustave Roussy, Villejuif, France
| | - D. Sinnett
- Sainte Justine Hospital, Montreal, QC, Canada; CHU Sainte Justine, Montreal, QC, Canada; Shiga University of Medical Sceince, Otsu, Ireland; Insitut Gustave Roussy, Villejuif, France
| | - C. Laverdiere
- Sainte Justine Hospital, Montreal, QC, Canada; CHU Sainte Justine, Montreal, QC, Canada; Shiga University of Medical Sceince, Otsu, Ireland; Insitut Gustave Roussy, Villejuif, France
| | - L. Oligny
- Sainte Justine Hospital, Montreal, QC, Canada; CHU Sainte Justine, Montreal, QC, Canada; Shiga University of Medical Sceince, Otsu, Ireland; Insitut Gustave Roussy, Villejuif, France
| | - G. Vassal
- Sainte Justine Hospital, Montreal, QC, Canada; CHU Sainte Justine, Montreal, QC, Canada; Shiga University of Medical Sceince, Otsu, Ireland; Insitut Gustave Roussy, Villejuif, France
| |
Collapse
|
43
|
Regairaz M, Munier F, Sartelet H, Marty V, Castaing M, Michiels S, Fabre M, Roesel J, Vassal G. Role of ALK activation in the development and maintenance of the neoplastic phenotype in neuroblastoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10008 Background: Activating mutations of the Anaplastic Lymphoma Kinase (ALK) receptor could be responsible for most familial neuroblastoma cases and for up to 15% of somatic cases. The objective of the present study was to further investigate the role of ALK activation in neuroblastoma. Methods: Tissue microarrays were constructed containing 101 primary tumors and 56 paired normal tissues. Sections were immunostained with anti-ALK or anti-P-ALK antibodies, and with antibodies directed against the ALK ligands: PTN (Pleiotrophin) or MDK (Midkine). The Wilcoxon signed rank test was applied for comparison of paired data. Associations with prognostic factors were analyzed using t-tests. Effects of the ALK inhibitor TAE684 (Novartis) on cell proliferation and signaling was evaluated in wild-type or mutated ALK neuroblastoma cell lines and xenografts. Results: ALK was expressed in about 100% of tumors and normal tissues, while phospho-ALK was detected in 5% of normal tissues and 50% of tumors. Sequencing of the kinase domain of ALK showed that its phosphorylation was largely independent of mutations and we found that MDK and PTN ligands were expressed in 66% and 50% of tumors, respectively. Interestingly, ALK, P-ALK, and MDK were expressed at higher levels in tumors as compared with paired normal tissues (p < 0.0001), while PTN showed an inverse tendency, being more expressed in normal tissues (p = 0.07). In tumors, P-ALK was associated with good-prognosis factors, including favorable stages (p = 0.01), absence of MYCN amplification (p = 0.05) and a younger age at diagnosis (p = 0.03). Inhibition of cell proliferation by TAE684 was detectible in all neuroblastoma cell lines, regardless of ALK status. However, TAE684 failed to demonstrate antitumor activity in advanced stage neuroblastoma xenografts expressing either a wild-type or a mutated ALK. Interestingly, ALK pathway activation (P-STAT3, P-AKT) was weak or barely detectible in these xenografts. Conclusions: ALK activation occurs during neuroblastoma oncogenesis, along with a concomitant switch between the expressions of PTN and MDK. However, ALK may not be a relevant therapeutic target since in vivo inhibition showed no antitumor activity. [Table: see text]
Collapse
Affiliation(s)
- M. Regairaz
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - F. Munier
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - H. Sartelet
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - V. Marty
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - M. Castaing
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - S. Michiels
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - M. Fabre
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - J. Roesel
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - G. Vassal
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| |
Collapse
|
44
|
Taylor M, Geoerger B, Lagodny J, Farace F, Vassal G, Rössler J. [Potential role of antiangiogenic treatment in neuroblastoma]. Arch Pediatr 2009; 16:457-67. [PMID: 19299115 DOI: 10.1016/j.arcped.2009.02.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2008] [Revised: 09/17/2008] [Accepted: 02/01/2009] [Indexed: 10/21/2022]
Abstract
Focus on new drug development over the last few years has yielded new agents that differ from unspecific classical chemotherapeutics and ionizing radiation, while still targeting the cancer cell itself. Antiangiogenesis is a totally distinct approach targeting the tumor's blood vessels. This concept has now found its eligibility for the treatment of several adult solid tumors: the human antivascular endothelial growth factor (VEGF) antibody bevacizumab, as well as the VEGF receptor tyrosine kinase inhibitors, sunitinib and sorafinib, have recently been licensed by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of colorectal, renal, and lung cancer. Other antiangiogenic drugs are under preclinical and early clinical evaluation. However, what do we know of the use of these drugs in pediatric solid tumors, such as sarcomas and embryonal and neuronal tumors? For some time now, neuroblastoma has been shown to be dependent on angiogenesis. However, the first preclinical data on antiangiogenic drugs in neuroblastoma have not been published until recently, and clinical trials with antiangiogenic agents in neuroblastoma treatment protocols are scarce. This review adresses current knowledge on the important role and mechanisms of angiogenesis in neuroblastoma and summarizes available preclinical and clinical results of antiangiogenic agents used to treat neuroblastoma. Our review clearly demonstrates that clinical trials are urgently needed to bring forward promising antiangiogenesis concepts in neuroblastoma therapy.
Collapse
Affiliation(s)
- M Taylor
- Institut Gustave-Roussy, UPRES EA3535 Pharmacologie et nouveaux traitements dans le cancer, université Paris-Sud, 63, rue Gabriel-Péri, 94276 Le Kremlin-Bicêtre, France
| | | | | | | | | | | |
Collapse
|
45
|
Geoerger B, Hamelin N, Rodier P, Opolon P, Versace R, Vassal G. 596 POSTER The topoisomerase I inhibitor gimatecan exhibits synergistic activity with temozolomide and tyrosine kinase inhibitors in malignant glioma xenografts. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72530-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
46
|
Geoerger B, Lanvers C, Verschuu A, Aviles P, Cuevas C, Boos J, Vassal G, Caron H. 181 POSTER Evaluation of the marine compound PM02734 against a pediatric tumor cell line panel by ITCC preclinical drug evaluation program. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72113-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
47
|
Verschuur A, Lanvers C, Geoerger B, Aviles P, Rodier P, Cuevas C, Boos J, Vassal G, Caron H. 193 POSTER Preclinical evaluation of the marine compound PM00104 within the ITCC pediatric tumor cell line panel in vitro and in vivo. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72125-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
48
|
Geoerger B, Brasme J, Daudigeos E, Bladt F, Venot C, Debussche L, Vrignaud P, Vassal G. 562 POSTER The anti-insulin-like growth factor I receptor antibody EM164 (murine AVE1642) enhances anti-tumor activity of temozolomide against neuroblastoma cell lines and xenografts. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72496-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
49
|
Vassal G. 15 INVITED Early drug development in the childrens' clinics in Europe. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)71947-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
50
|
Geoerger B, Doz F, Lowis S, Kearns P, Estlin E, Gibson B, Corradini N, Lardelli P, Vassal G. Phase I-II clinical and pharmacokinetic study of plitidepsin in children with malignant tumors. On behalf of the European ITCC (Innovative Therapies for Children with Cancer) Consortium. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.10028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|